Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q4 FY2021 Earnings Presentation
9 slides from Angiodynamics's earnings presentation, Jul 13, 2021
Slide 1: Fourth Quarter 2021 Earnings Presentation
ANGIODYNAMICS Fourth Quarter 2021 Earnings PresentationJuly 13, 2021 1
Slide 2: Forward-Looking Statement
2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Corporate Developments – Q4 Highlights
Corporate Developments – Q4 Highlights 3 108% growth in AngioVac YOY$4.6 million in Auryon sales NanoKnife disposable growth: US 69% YOY; worldwide growth of 42% YOY YOY comparisons are significantly impacted by the COVID-19 global pandemicProcedural volumes continued to rebound in Q4 AngioVac cases
Slide 4: Fourth Quarter and FY2021 Highlights
Fourth Quarter and FY2021 Highlights $ in thousands (except per share data) Q4 FY2021 Q4 FY2020 YOY Change Revenue $76,842 $58,332 31.7% Gross Margin 55.1% 51.8% 330 bps Net Loss ($19,468) ($157,067) $137,599 GAAP EPS ($0.51) ($4.13) $3.62 Adjusted EPS $0.00 ($0.06) $0.06 Adjusted EBITDA $4,512 $553
Slide 5: Fourth Quarter and FY2021 Highlights – Additional Detail
Fourth Quarter and FY2021 Highlights Sales Growth Over Prior Year Periods – Additional Detail Med Tech Q4 FY2021 FY2021 Auryon NA** NA** Mechanical Thrombectomy* 62% 32% NanoKnife® Disposables 42% 13% NanoKnife® Capital (77%) (48%) Med Device Q4 FY2021 FY2021 Solero® Microwave 38% 11% BioSentry 93%
Slide 6: Fourth Quarter and FY2021 Results (unaudited)
Fourth Quarter and FY2021 Results (unaudited) $ in thousands (except per share data) Q4 FY2021 Q4 FY2020 Change FY2021 FY2020 Change Revenue Endovascular Therapies (formerly VIT) Vascular Access Oncology United States International $76,842$38,071$24,462$14,309$63,597$13,245 $58,332$22,090$23,714$12,
Slide 7: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 7
Slide 8: Reconciliation of GAAP to Non-GAAP Net Income and EPS
Reconciliation of GAAP to Non-GAAP Net Income and EPS Reconciliation of Net Loss to Adjusted EBITDA Write-off of raw materials and existing dosimetry inventory associated with OARtrac that was purchased pursuant to the Company’s acquisition of RadiaDyne. These inventory items were deemed unmarketabl
Slide 9: AngioDynamics
®D angiodynamics